Research programme: microbiome therapeutics - Debiopharm/Takeda
Alternative Names: 1454M programme - Debiopharm/Takeda; Debio-1454/M; Microbiome remodeling program - Debiopharm/TakedaLatest Information Update: 28 Jul 2024
At a glance
- Originator Debiopharm
- Developer Debiopharm; Takeda
- Class Anti-inflammatories
- Mechanism of Action Gastrointestinal microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Gastrointestinal disorders; Inflammatory bowel diseases
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for preclinical development in Gastrointestinal-disorders in Japan
- 28 Jul 2024 No recent reports of development identified for preclinical development in Gastrointestinal-disorders in Switzerland
- 28 Jul 2024 No recent reports of development identified for preclinical development in Inflammatory-bowel-diseases in Japan